An investigation has uncovered evidence of significant misreporting, raising new concerns about the approval and long-term use of ticagrelor over the past decade. In a follow-up investigation into the ...

In 2022, “Ticagrelor Market “Size, Status and Market Insights, the worldwide market for Ticagrelor is anticipated to rise at a considerable rate during the forecast period, between 2022 and ...

The combination of ticagrelor and aspirin prevents secondary stroke and cuts mortality, but it also appears to increase the risk for severe bleeding.

Ticagrelor (Astra Zeneca - Brilinta®, Brilique®) is one of the most commonly used anti-platelet drugs to reduce the risk of cardiac death, heart attacks, and strokes in patients with either a ...

Ticagrelor was approved by the FDA in July with an indication to reduce the rate of thrombotic cardiovascular events in patients with ACS.

Experts suggest that ticagrelor provides considerable added benefit to specific patients by decreasing the risk of death and myocardial infarction.

Ticagrelor monotherapy after 3-month dual antiplatelet therapy was not associated with greater risk for repeat revascularization or MACCE at 1 year after PCI vs. continued DAPT, a speaker reported ...

Ticagrelor is as safe and effective as clopidogrel after heart attack Potent blood-thinner found safe but not superior to clopidogrel for those given clot busters Date: March 18, 2019 Source ...

Ticagrelor’s Dominance Over Clopidogrel Again Questioned With another observational study in ACS challenging the more potent P2Y12 inhibitor, one researcher predicts a practice shift.

The authors of the study also suggest that ticagrelor may inhibit platelets more effectively than prasugrel.

The FDA has approved ticagrelor (Brilinta, AstraZeneca). In a press release, the FDA said that the drug was approved to reduce cardiovascular death and MI in patients with acute coronary syndromes ...

CytoSorb is the only approved therapy to remove ticagrelor in the European Union, and is intended to address a major unmet medical need of potentially life-threatening postoperative bleeding in ...